US20060199263A1 - Method of isolating cells from umbilical cord - Google Patents

Method of isolating cells from umbilical cord Download PDF

Info

Publication number
US20060199263A1
US20060199263A1 US11/314,153 US31415305A US2006199263A1 US 20060199263 A1 US20060199263 A1 US 20060199263A1 US 31415305 A US31415305 A US 31415305A US 2006199263 A1 US2006199263 A1 US 2006199263A1
Authority
US
United States
Prior art keywords
cells
umbilical cord
cell types
vein
smooth muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/314,153
Other languages
English (en)
Inventor
Francois Auger
Lucie Germain
Murielle Remy-Zolghadri
Cindy Hayward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to UNIVERSITE LAVAL reassignment UNIVERSITE LAVAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAYWARD, CINDY J., REMY-ZOLGHADRI, MURIELLE, AUGER, FRANCOIS A., GERMAIN, LUCIE
Publication of US20060199263A1 publication Critical patent/US20060199263A1/en
Priority to US11/924,661 priority Critical patent/US7939323B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Definitions

  • the present invention relates to a method for isolating four cell types from the umbilical cord, and more particularly from the umbilical vein, in good conditions without having to execute separate methods for each type of cell.
  • the method is of particular importance for obtaining a variety of different cells in good condition from only one tissue.
  • stem cells are capable of self-regeneration but may also divide into progenitor cells that are no longer pluripotent nor capable of self-regeneration. These progenitor cells divide repeatedly to form more mature cells, which eventually become terminally differentiated to form various mature cells. Thus the large number of mature cells is derived from a small reservoir of stem cells by a process of proliferation and differentiation.
  • tissue-engineered blood vessels should provide mechanically stable vessels built only from autologous tissue, therefore generating no immune responses.
  • Tissue engineering has been used successfully in the past to build less complex structures such as skin, but has had only relative success with other three-dimensional tissues and organs such as tissue-engineered blood vessels.
  • Common problems associated with three-dimensional engineered tissues include the complexity of reconstruction, the lack of structural integrity and mechanical strength, and the need for biologically active tissues.
  • tissue-engineered blood vessels This is a particular problem for tissue-engineered blood vessels, since these vessels will be subjected to significant mechanical loads both from blood pressure (which may be abnormally high in patients with heart disease), as well as from the relative motion between the anchoring sites of the vessel. Moreover, the tissue-engineered blood vessels must demonstrate sufficient stability and tear resistance to allow surgical handling and implantation, and require a biologically active endothelial layer.
  • Stem cells mature into progenitor cells and then become lineage committed, that is, incapable of maturing into all of the different lineages which the stem cell is capable of producing.
  • Highly purified populations of stem cells currently find use in the long-term repopulation of particular body systems.
  • Purified progenitor cells of individual lineages would find use only in transiently repopulating or augmenting the various lineages. As progenitors are not believed to be self-regenerating, the repopulation or augmentation would be limited, for example, to short-term tissue-specific reconstitution.
  • tissue engineering uses living cultured human or animal cells from various sources to reconstruct functional tissues and organs for experimental and therapeutic purposes.
  • cord stem cell preparations are presently under investigation.
  • progenitor cells may have to be separated through carrying out parallel methods upon different sources of living tissues. Separation requires identification of the cells and characterization of phenotypic differences that can be utilized in a separation procedure.
  • methods known at this time for preparing replacement tissues still have to be carried out with cells originating from heterologous sources, therefore creating problems of compatibility in using such replacement tissues.
  • the cells originating from the umbilical cord tissue remain underused both as progenitor cells, and in complex cell compositions for the preparation of replacement and engineered tissues.
  • a method for the simultaneous isolation of four cell types from one umbilical cord sample comprising the steps of:
  • step b) treating said umbilical cord biopsy of step a) with a solution of trypsin-EDTA for a time sufficient to allow detachment of epithelial cells;
  • the invention also provides for the use of the above-mentioned four cell types for the preparation of a replacement or engineered tissue or graft.
  • the invention additionally relates to a biological composition comprising these four cell types.
  • progenitor or “progenitor cells” as used herein are intended to indicate cell populations which are no longer stem cells but which have not yet become terminally differentiated or which still have a certain level of flexibility and adaptability.
  • FIG. 1 illustrates the typical aspects of the four cell types in monolayer culture, in phase contrast photographs
  • FIG. 2 illustrates sections of the umbilical cord before and after the extraction of endothelial cells, and endothelial cells in culture immunolabelled for van Willebrand factor;
  • FIG. 3 illustrates sections of the umbilical cord before and after the extraction of smooth muscle cells, and smooth muscle cells in culture immunolabelled for ⁇ -smooth muscle actin;
  • FIG. 4 illustrates sections of the umbilical cord before and after the extraction of fibroblasts, and fibroblasts in culture immunolabelled for vimentin;
  • FIG. 5 illustrates sections of the umbilical cord before and after the extraction of epithelial cells, and epithelial cells in culture immunolabelled for desmoplakin.
  • a method for isolating four cell types from only one umbilical cord section in successive steps allowing each cell type to be kept in good physiological condition after each isolation step.
  • the advantage of the present invention over the prior art will be recognized as providing a method allowing the preparation of four umbilical cell types in which after each step, all the desired types of cells are kept alive and in condition to be harvested for further uses. No equivalent techniques in the art are known to allow a skilled person to isolate four cell types from a single tissue biopsy without significant cell mortality and tissue destruction.
  • the inventors have developed a method for the extraction of four distinct cell types from a single umbilical cord biopsy or section. This permits the conservation of multiple cell types from a unique source, or from only one person, for present or future therapeutic applications, and this also permits research using tissue models fabricated with cells of the same lineage.
  • autologous cells are harvested from the patient's own body to eliminate the risks of disease transmission and tissue rejection.
  • All umbilical cord biopsies contain endothelial cells, epithelial cells, smooth muscle cells, and fibroblasts. Therefore, almost any biopsy procedure or tissue harvest will provide a suitable starting point for the four of them.
  • the umbilical cord is of particular interest as a source of cell lines because of its foetal condition, and because its obtention is simple and non-invasive.
  • the present invention is directed to a method for the extraction of four cell types: epithelial cells, fibroblasts, smooth muscle cells and endothelial cells, as pure cultures from a single human umbilical cord.
  • the human umbilical cord is a foetal structure that carries blood from the foetal circulation to the placenta for oxygenation via the two umbilical arteries, and returns the oxygenated blood to the developing child by way of the umbilical vein.
  • the blood vessels are lined with endothelial cells, which are in turn surrounded by a substantial layer of smooth muscle cells (SMC), thicker around the arteries than around the vein.
  • SMC smooth muscle cells
  • the bundle of blood vessels is enclosed in turn by a thick layer of extracellular matrix sparsely populated by fibroblasts and known as Wharton's jelly.
  • a thin layer of epithelial cells covers the outer surface of the umbilical cord.
  • the umbilical cord epithelium is formed of a thin layer of epithelial cells resting on a basement membrane, and is the only part of the umbilical cord to be in contact with the surrounding amniotic fluid, thus acting as a barrier between the internal tissues and the outer liquid. It is often only a single cell layer thick, but regions of up to five layers of thickness do occur.
  • the epithelium of the cord is contiguous both with the amniotic epithelium, from which it is derived in the early stages of development, as well as with the early embryonic periderm and the later foetal epithelium.
  • the morphology of the umbilical cord epithelium has been described as being closely related to the early foetal epidermis before its keratinisation.
  • This process does not occur normally in the umbilical cord epithelium except in the region adjacent to the foetus, the rest of the epithelium remaining as a simple squamous epithelium.
  • the epithelial cells are tightly joined to each other by numerous desmosomes, and to the underlying basement membrane by hemidesmosomes.
  • the dense cytoskeleton contains keratin fibres of many types, the presence of which is typical of epithelia. Few studies have been done to further characterize these cells.
  • the connective tissue of the umbilical cord commonly called Wharton's jelly, consists of fibroblasts dispersed within a loose mucous connective tissue, composed mainly of a network of collagen fibres and a ground substance of glycosaminoglycans, mostly hyaluronic acid, along with an independent fibrillar network of glycoprotein microfibrils. This tissue serves to protect the umbilical blood vessels from compression and torsion.
  • fibroblasts themselves are somewhat unusual as they combine characteristics of both typical fibroblastic cells (abundant Golgi apparati, collagen secretion granules, mitochondria and rough endoplasmic reticulae) and of smooth muscle cells (deeply indented nuclei, pinocytotic vesicles and fibronexus junctions). Their content of ⁇ -smooth muscle actin gives them a certain contractility. Desmin and non-muscle myosin have also been identified as intracellular components. There is disagreement on the exact nature and origin of these cells because of their diverse characteristics, and further analysis will be necessary to shed light on their exact role.
  • Smooth muscle cells form the ring-shaped media that surround the arteries and vein of the umbilical cord. Their main function is contraction, but these cells are also capable of many other functions when required, including production of extracellular matrix proteins and increased cell proliferation. Typical components of the smooth muscle cell include smooth muscle actin, myosin, calponin, caldesmon, vinculin, tropomyosin, vimentin and desmin. Many and varied ion channels and membrane receptors allow sensitive regulation of the contractile behaviour of these cells. Smooth muscle cells derived from the umbilical cord have been extensively used in the study of smooth muscle cells, their metabolism and their characteristics, as well as in tissue reconstructions.
  • the umbilical cord vein and arteries are lined by endothelial cells, which have many diverse functions in the body, including the maintenance of a non-thrombogenic intimal surface, the regulation of coagulation and fibrinolysis, immunological functions, the regulation of perfusion and permeability across the vessel walls, and the release of and response to chemical agents.
  • Endothelial cells harvested from umbilical cord blood vessels and other sources have been used for numerous experimental purposes for many years, especially for studies on angiogenesis and its control by pharmacological manipulation, and have been well characterized. They are known by their typical cobblestone shape in monolayer culture, and their ability to form tubules when plated in three-dimensional gels and collagen sponges. Universal cellular markers for endothelial cells include the adhesion molecule CD-31 and the von Willebrand factor.
  • the object of the present invention is to provide a method to isolate pure cell lines of four different cell types from a single umbilical cord.
  • the cell lines can then be utilised in the reconstruction of multilineage tissues, including but not limited to vascular structures.
  • These reconstructions are of interest and value not only for the study of the interactions between cells and cell types but also in a long-term therapeutic view, wherein the cells from a person's umbilical cord could be conserved and ultimately serve in the replacement of diseased or damaged tissues.
  • Endothelial cells, epithelial cells, fibroblasts and smooth muscle cells can be isolated from the biopsy by techniques described herein.
  • the invention essentially consists of enzymatic digestion in specific media and manual dissection of the umbilical cord tissue to separate the cell-containing tissues. Fibroblasts and smooth muscle cells can be harvested from tissue explants of the biopsy by cell outgrowth or by enzymatically digesting the explants and plating the digested tissue.
  • Mature engineered living structures of isolated cells can include, but are not limited to, their own extracellular matrix proteins. Additional cells can be added to the four cell types at any stage of tissue formation. These cells can include additional human or animal cells or transfected or otherwise genetically modified cells.
  • One particular embodiment of the present invention is to provide a composition of four cell types isolated from the same autologous source and having a high progenitor potential.
  • An embodiment of the invention is directed to the use of neonatal progenitor cells for living or biological tissue reconstitution. There are several reasons for preferring the use of such neonatal cells to that of conventional mature cells. First, no donor is required because the cells can be obtained from neonatal umbilical cords that would otherwise be discarded. Second, in a preferred autologous system, i.e., involving use of “self” neonatal cells, the complications arising in conventional cell or tissue transplantation from the need for pretransplantation drug-induced or irradiation-induced immune incapacitation and from acute and chronic graft-versus-host disease are eliminated because, in this embodiment, neonatal cells are returned to their original owner and are therefore totally compatible.
  • the present method allows the provision of vascular cells for neovascularisation, and of fibroblastic cells for the reconstruction of mesenchymal structures such as ligament or cartilages.
  • fibroblastic cells have successfully been used in the allogeneic reconstruction of dermal tissue, and thus such allogeneic applications could equally be envisaged for the fibroblasts and other cell types of the umbilical cord.
  • the neonatal umbilical cord is a preferred source of cells for tissue reconstitution and engineering, since it is much less prone to microbial and viral contamination, known or unknown, latent or otherwise, that may be encountered in later life, other than those transmitted from the mother or during labor and delivery.
  • the known stem cells may possibly share with other cells the limitation in the total number of cell divisions that they may undergo before senescence, it is proper to assume that the neonatal umbilical progenitor cells have a self-renewal and reconstitutional capacity that is at least as great, and perhaps even greater, than that of cells obtained at any later time in life.
  • the umbilical cord was gently cleansed of blood and debris on the outer surface with a moist sterile gauze, and inspected for clamp marks, cuts and other analomies which might have damaged the internal structure of the cord and thus cause a mixing of the cell types extracted.
  • An undamaged section of the umbilical cord preferably greater than 15 cm in length, was used for the extraction of the endothelial cells.
  • the umbilical vein on one end of the section was cannulated using a small plastic adapter, a plastic tube attached to a stopcock capable of receiving a syringe, and a circular clamp, and the vein was rinsed 3 times with 10 mL of cold sterile Hepes 1 ⁇ .
  • the cord was removed from the container and very gently massaged in order to dislodge all the endothelial cells possible.
  • the vein was then rinsed with 30 mL warm Hepes and the perfusion liquid collected in a centrifugation tube partially filled with M199 complete medium.
  • the cells were then pelleted by centrifugation, resuspended and plated in gelatinated culture flasks with the same medium.
  • the section of the umbilical cord used for the extraction of endothelial cells was subsequently used for the extraction of the epithelial cells.
  • the greatest portion possible of the cord was placed in a sterile container with slots cut in opposing sides to hold the ends of the cord out of the enzymatic solution.
  • the container was then filled as full as possible with approximately 40 mL of trypsin 0.25% EDTA, sealed and placed at 37° C. with gentle agitation for 5 min.
  • the enzymatic solution was then discarded and replaced with a fresh aliquot. Successive incubation times of 15, 15, and 30 min. were then undertaken. After each incubation period serum was added as a trypsin inhibitor to the collected solution of trypsin, and the mixture was centrifuged.
  • the pelleted cells from each fraction were resuspended in complete DME-Ham's 10% CS and pooled in order to perform a count of the cells obtained.
  • the cells were seeded in culture flasks with a feeder layer of murine Swiss 3T3 irradiated fibroblasts (S3T3) (20 000 cells/cm 2 ) at a density of 80 000 cells/cm 2 in DME-Ham's complete medium.
  • the section of umbilical cord from which the epithelial cells were extracted was used for the extraction of fibroblasts.
  • Thin slices of Wharton's jelly were taken from the surface of the umbilical cord with a scalpel, taking care not to cut into the vascular structures. These slices were immediately placed in cold culture medium (DME with 10% FCS). When all the explants had been taken, they were cut into small squares (2 mm) and rinsed several times with the same medium. They were then carefully placed in gelatin-coated culture flasks with a minimum of complete medium (1.4 mL per 25 cm 2 flask). No changes of culture medium were done before a minimum of 4 to 5 days. Once a sufficient number of cells had migrated outwards from the explants, they were dissociated using trypsin-EDTA, centrifuged and replated in culture flasks at a density of 10 000 cells per cm 2 .
  • the same section of umbilical cord was then cut into smaller sections and used for the extraction of smooth muscle cell explants.
  • the umbilical vein was opened with sterile scissors on the side opposing the location of the umbilical arteries. After pinning down the opened section on a dissection board with the inner vein surface uppermost, any remaining endothelial cells were removed with a moist sterile gauze. Thin strips or bands of smooth muscle tissue were detached using a sterile pair of curved jeweller's tweezers to lift them away from the surface and a scalpel to sever the ends of these strips. The explants were placed immediately in cold culture medium (DME-Ham's with 10% FCS).
  • DME-Ham's with 10% FCS cold culture medium
  • Endothelial cells M199 (Sigma # 5017) reconstituted with apyrogenic water and 2.2 g/L sodium bicarbonate, 20% calf serum (Hyclone), 20 mg/mL endothelial cell growth factor (Sigma E-2759), 2.28 mM glutamine (GLNS), 0.40 U/mL heparin, 100 UI/mL penicillin G, 25 mg/mL gentamycin sulphate.
  • Smooth muscle cells Dulbecco-Vogt modified Eagle's medium and Ham's F12 (3:1 mixture), 10% foetal calf serum (Biomedia), 100 UI/mL penicillin G, 25 mg/mL gentamycin sulphate.
  • Fibroblasts Dulbecco-Vogt modified Eagle's medium, 10% foetal calf serum (Hyclone) 100 UI/mL penicillin G, 25 mg/mL gentamicin sulphate.
  • Epithelial cells Dulbecco-Vogt modified Eagle's medium and Ham's F12 (3:1 mixture), 10% calf serum (Hyclone), 10 ng/mL epidermal growth factor, 5 mg/mL insulin, 1 ⁇ 10-10 M cholera toxin, 5 mg/mL transferrin, 2 ⁇ 10-9 M 3,3′,5triiodo-L-thyronine, 0.4 mg hydrocortisone, 100 UI/mL penicillin G, 25 mg/mL gentamycin sulphate.
  • All four cell types could be established and maintained in culture using the aforementioned combination of extraction techniques. Each cell type has its characteristic phenotype and proliferation profile, as well as its particular requirements insofar as culture conditions.
  • FIG. 1 the typical aspects of the different cell types in monolayer culture are illustrated; in a) endothelial cells, in b) smooth muscle cells, in c) fibroblasts, and in d) a proliferative colony of epithelial cells surrounded by feeder S3T3 cells. All photographs were taken at 10 ⁇ magnification under phase contrast.
  • FIG. 2 a shows a section of umbilical cord vein with the layer of endothelial cells overlying the media (smooth muscle cells), at 40 ⁇ magnification. After the extraction of the endothelial cells, an intact media remains ( FIG. 2 b, 20 ⁇ magnification).
  • FIG. 3 a shows a section of umbilical cord vein with the layers of smooth muscle cells overlying the connective tissue called Wharton's jelly, 40 ⁇ magnification.
  • FIG. 4 a a section of umbilical cord shows the connective tissue called Wharton's jelly surrounding part of the umbilical cord vein, 10 ⁇ magnification. After extraction of the fibroblasts, FIG. 4 b shows no ingression into the media surrounding the vein (4 ⁇ magnification).
  • FIG. 5 a a section of umbilical cord shows the epithelium overlying the connective tissue called Wharton's jelly, at 40 ⁇ magnification. After extraction of the epithelial cells, FIG. 5 b shows no break in the basement membrane underlying the epithelial cells and no ingression into the connective tissue of Wharton's jelly (40 ⁇ magnification).
  • FIG. 2 c shows the presence of von Willebrand factor in the endothelial cells
  • FIG. 3 c illustrates the marking of smooth muscle a-actin in smooth muscle cells
  • FIG. 4 c demonstrates the presence of vimentin, a structural protein common to fibroblastic cells, in the fibroblasts of Wharton's jelly (all at 40 ⁇ magnification)
  • FIG. 5 c shows the marking of desmoplakin, a protein of adhesion particular to epithelial cells, in cultured epithelial cells (60 ⁇ magnification).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US11/314,153 2003-06-27 2005-12-21 Method of isolating cells from umbilical cord Abandoned US20060199263A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/924,661 US7939323B2 (en) 2003-06-27 2007-10-26 Method of isolating cells from umbilical cord

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2003/000979 WO2005001081A1 (fr) 2003-06-27 2003-06-27 Methode permettant d'isoler des cellules du cordon ombilical

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/000979 Continuation WO2005001081A1 (fr) 2003-06-27 2003-06-27 Methode permettant d'isoler des cellules du cordon ombilical

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/924,661 Continuation US7939323B2 (en) 2003-06-27 2007-10-26 Method of isolating cells from umbilical cord

Publications (1)

Publication Number Publication Date
US20060199263A1 true US20060199263A1 (en) 2006-09-07

Family

ID=33546112

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/314,153 Abandoned US20060199263A1 (en) 2003-06-27 2005-12-21 Method of isolating cells from umbilical cord
US11/924,661 Expired - Fee Related US7939323B2 (en) 2003-06-27 2007-10-26 Method of isolating cells from umbilical cord

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/924,661 Expired - Fee Related US7939323B2 (en) 2003-06-27 2007-10-26 Method of isolating cells from umbilical cord

Country Status (6)

Country Link
US (2) US20060199263A1 (fr)
EP (1) EP1639099B1 (fr)
AT (1) ATE510005T1 (fr)
AU (1) AU2003304250A1 (fr)
CA (1) CA2529718C (fr)
WO (1) WO2005001081A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148074A1 (en) * 2003-02-11 2005-07-07 Davies John E. Progenitor cells from wharton's jelly of human umbilical cord
US20080050814A1 (en) * 2006-06-05 2008-02-28 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of fetal placental cells
US20080064098A1 (en) * 2006-06-05 2008-03-13 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of maternal placental cells
WO2008060037A1 (fr) * 2006-11-15 2008-05-22 Seoul National University Industry Foundation Procédé d'isolement primaire et d'expansion de cellule endothéliale souche/parente et de cellule souche mésenchyme derivées d'un cordon ombilical de mammifère, notamment humain
WO2008153231A1 (fr) * 2007-06-13 2008-12-18 Chabiotech Co., Ltd. Procédé d'isolement de cellules vasculaires endothéliales de corps embryoïdes différenciés de cellules souches enbryonnaires
US20090275127A1 (en) * 2005-12-22 2009-11-05 Jane Ennis Viable cells from frozen umbilical cord tissue
US20090285842A1 (en) * 2006-05-05 2009-11-19 Davies John E Immune privileged and modulatory progenitor cells
US20100233131A1 (en) * 2008-06-26 2010-09-16 Pusan National University Industry-University Coop Selenium dedifferentiated cell, preparation method and usage thereof
US20110177023A1 (en) * 2008-04-21 2011-07-21 Jane Elizabeth Ennis Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US20130095143A1 (en) * 2010-03-30 2013-04-18 Histocell, S.L. Biomaterial from wharton's jelly umbilical cord
US8940294B2 (en) 2012-03-02 2015-01-27 Tissuetech, Inc. Methods of isolating and culturing stem cells
CN115322949A (zh) * 2022-07-26 2022-11-11 唐颐控股(深圳)有限公司 一种人脐静脉平滑肌细胞的分离培养方法及其应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1789534T3 (pl) 2004-08-16 2015-03-31 Cellresearch Corp Pte Ltd Wyodrębnienie komórek macierzystych/progenitorowych z błony owodniowej pępowiny
US9944900B2 (en) 2006-01-18 2018-04-17 Hemacell Perfusion Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells
US8673547B2 (en) * 2007-03-08 2014-03-18 Hemacell Perfusion, Inc. Method for isolation of afterbirth derived cells
EP2199383B1 (fr) * 2008-12-22 2017-02-15 SpheroTec GmbH Procédé pour la préparation de fibroblastes
WO2012048276A2 (fr) 2010-10-08 2012-04-12 Caridianbct, Inc. Procédés et systèmes configurables pour la culture et la récolte de cellules dans un système de bioréacteur à fibres creuses
EP2785839A2 (fr) 2011-11-30 2014-10-08 University of Bremen Expression d'arnmi dans le tissu placentaire
BR102013021202B1 (pt) * 2013-08-20 2022-09-06 Ccb - Centro De Criogenia Brasil Ltda Processo de produção de células tronco multipotentes e progenitores
WO2015073913A1 (fr) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expansion de cellules dans un bioréacteur
WO2015148704A1 (fr) 2014-03-25 2015-10-01 Terumo Bct, Inc. Remplacement passif de milieu
EP3198006B1 (fr) 2014-09-26 2021-03-24 Terumo BCT, Inc. Alimentation programmée
CN104894088A (zh) * 2015-05-29 2015-09-09 广州赛莱拉干细胞科技股份有限公司 消化酶组合物及其应用、脐带上皮细胞的分离培养方法
WO2017004592A1 (fr) 2015-07-02 2017-01-05 Terumo Bct, Inc. Croissance cellulaire à l'aide de stimuli mécaniques
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP4314244B1 (fr) 2021-03-23 2025-07-23 Terumo BCT, Inc. Capture et multiplication cellulaire
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134065A (en) 1986-05-16 1992-07-28 Monsanto Company Tissue plasminogen activator inhibitor and method of purification
US5919702A (en) 1996-10-23 1999-07-06 Advanced Tissue Science, Inc. Production of cartilage tissue using cells isolated from Wharton's jelly
US6537567B1 (en) 1997-07-03 2003-03-25 Massachusetts Institute Of Technology Tissue-engineered tubular construct having circumferentially oriented smooth muscle cells
AU3568899A (en) 1998-04-17 1999-11-08 Science Research Laboratory, Inc. Isolation and purging of cells by means of osmotic pressure
JP2000139454A (ja) 1998-11-04 2000-05-23 Asahi Medical Co Ltd 細胞分離回収方法及び回収必要細胞含有液
AU4860900A (en) * 1999-06-02 2000-12-18 Lifebank Services, L.L.C. Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
US20020045260A1 (en) 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
DK1349918T3 (da) * 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
IL158171A0 (en) 2001-04-10 2004-03-28 Bioergonomics Inc Compositions and methods for cell separation

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611456B2 (en) 2003-02-11 2017-04-04 Tissue Regeneration Therapeutics Inc. Progenitor cells from wharton'S jelly of human umbilical cord
US9567564B2 (en) 2003-02-11 2017-02-14 Tissue Regeneration Therapeutics Inc. Progenitor cells from Wharton's jelly of human umbilical cord
US20050148074A1 (en) * 2003-02-11 2005-07-07 Davies John E. Progenitor cells from wharton's jelly of human umbilical cord
US7547546B2 (en) 2003-02-11 2009-06-16 Tissue Regeneration Therapeutics Inc. Progenitor cells from wharton's jelly of human umbilical cord
US20090269318A1 (en) * 2003-02-11 2009-10-29 Tissue Regeneration Therapeutics, Inc. Progenitor cells from wharton's jelly of human umbilical cord
US8481311B2 (en) 2003-02-11 2013-07-09 Tissue Regeneration Therapeutics Inc. Progenitor cells from wharton's jelly of human umbilical cord
US8278102B2 (en) 2005-12-22 2012-10-02 Jane Ennis Viable cells from frozen umbilical cord tissue
US8790923B2 (en) 2005-12-22 2014-07-29 Jane E. Ennis Viable cells from frozen umbilical cord tissue
US20090275127A1 (en) * 2005-12-22 2009-11-05 Jane Ennis Viable cells from frozen umbilical cord tissue
US8900573B2 (en) 2006-05-05 2014-12-02 John E. Davies Immune privileged and modulatory progenitor cells
US8277794B2 (en) 2006-05-05 2012-10-02 Davies John E Immune privileged and modulatory progenitor cells
US20090285842A1 (en) * 2006-05-05 2009-11-19 Davies John E Immune privileged and modulatory progenitor cells
US20080064098A1 (en) * 2006-06-05 2008-03-13 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of maternal placental cells
US20080050814A1 (en) * 2006-06-05 2008-02-28 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of fetal placental cells
WO2008060037A1 (fr) * 2006-11-15 2008-05-22 Seoul National University Industry Foundation Procédé d'isolement primaire et d'expansion de cellule endothéliale souche/parente et de cellule souche mésenchyme derivées d'un cordon ombilical de mammifère, notamment humain
US7919318B2 (en) 2007-06-13 2011-04-05 Chabio & Diostech Co., Ltd. Process for isolating vascular endothelial cells from embryoid bodies differentiated from embryonc stem cells
WO2008153231A1 (fr) * 2007-06-13 2008-12-18 Chabiotech Co., Ltd. Procédé d'isolement de cellules vasculaires endothéliales de corps embryoïdes différenciés de cellules souches enbryonnaires
US20100144032A1 (en) * 2007-06-13 2010-06-10 Chabiotech Co., Ltd. Process for isolating vascular endothelial cells from embryoid bodies differentiated from embryonc stem cells
US9498544B2 (en) 2008-04-21 2016-11-22 Tissue Regeneration Therapeutics Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US20110177023A1 (en) * 2008-04-21 2011-07-21 Jane Elizabeth Ennis Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US9005599B2 (en) 2008-04-21 2015-04-14 Tissue Regeneration Therapeutics Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US20100233131A1 (en) * 2008-06-26 2010-09-16 Pusan National University Industry-University Coop Selenium dedifferentiated cell, preparation method and usage thereof
US20130095143A1 (en) * 2010-03-30 2013-04-18 Histocell, S.L. Biomaterial from wharton's jelly umbilical cord
US10226480B2 (en) * 2010-03-30 2019-03-12 Histocell, S.L. Biomaterial from Wharton's jelly umbilical cord
US8940294B2 (en) 2012-03-02 2015-01-27 Tissuetech, Inc. Methods of isolating and culturing stem cells
CN115322949A (zh) * 2022-07-26 2022-11-11 唐颐控股(深圳)有限公司 一种人脐静脉平滑肌细胞的分离培养方法及其应用

Also Published As

Publication number Publication date
CA2529718C (fr) 2012-10-23
US7939323B2 (en) 2011-05-10
WO2005001081A1 (fr) 2005-01-06
EP1639099A1 (fr) 2006-03-29
ATE510005T1 (de) 2011-06-15
CA2529718A1 (fr) 2005-01-06
US20080102522A1 (en) 2008-05-01
EP1639099B1 (fr) 2011-05-18
AU2003304250A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
US7939323B2 (en) Method of isolating cells from umbilical cord
US5518915A (en) Three-Dimensional mucosal cell and tissue culture system
US5160490A (en) Three-dimensional cell and tissue culture apparatus
US7419661B2 (en) Dermal sheath tissue in wound healing
CA2183555C (fr) Reproduction et utilisation de tissu humain fonctionnel
CN100503814C (zh) 一种用于治疗皮肤缺损的可移植性产品的制备方法
CN101330935A (zh) 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用
HUT56393A (en) Three dimensional cell and tissue culturing systems
CN104263699A (zh) 细胞移植用临床治疗级真皮多能干细胞规模化制备培养方法
CN115418341B (zh) 成纤维细胞向毛乳头细胞转分化的方法及其应用
US20200078492A1 (en) Process for obtaining a functional dermal substitute of decellurized amniotic membrane from the placenta combination with keratinocytes and its use as an agent for tissue regeneration of the skin
CN104263698A (zh) 临床治疗级细胞治疗用成纤维细胞规模化制备人类细胞外基质筛选培养方法
EP0980270B1 (fr) Tissu de gaine dermique pour la cicatrisation
Pajoum et al. In vitro co-culture of human skin keratinocytes and fibroblasts on a biocompatible and biodegradable scaffold
CN103893831A (zh) 一种器官型人工皮肤、其制备方法及应用
US12234478B2 (en) Method of autologous primary hair follicles preparation in 3D culture
CN102552323B (zh) 加速皮肤修复与再生的药物及其制备方法和应用
Malik et al. Organ, histotypic and organotypic culture, and tissue engineering
CN114540281A (zh) 一种无血清培养基及其制备方法和应用
CN106962274A (zh) 一种组织工程皮肤修复裸鼠全层皮肤缺损的实验研究方法
CN1071568A (zh) 复合的活的皮肤等同物
AU4211489A (en) Three-dimensional cell and tissue culture system
JPS59501298A (ja) 骨同等物およびその製造法
Haegerstrand et al. Direct mounting of cultured epidermal grafts: A Way to Enhance the Transplantation Area

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITE LAVAL, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AUGER, FRANCOIS A.;GERMAIN, LUCIE;REMY-ZOLGHADRI, MURIELLE;AND OTHERS;REEL/FRAME:017528/0843;SIGNING DATES FROM 20060128 TO 20060324

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION